Alnylam Pharmaceuticals Book Value Per Share Growth & History (ALNY)
Alnylam Pharmaceuticals's book value per share was $5.96 for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.96 | $5.44 | +1048.94% |
| 2024 | 2024-12-31 | $0.52 | $2.27 | — |
| 2023 | 2023-12-31 | -$1.75 | -$0.48 | — |
| 2022 | 2022-12-31 | -$1.28 | -$6.17 | — |
| 2021 | 2021-12-31 | $4.89 | -$3.83 | −43.93% |
| 2020 | 2020-12-31 | $8.73 | -$4.10 | −31.93% |
| 2019 | 2019-12-31 | $12.82 | -$0.04 | −0.34% |
| 2018 | 2018-12-31 | $12.87 | -$4.86 | −27.39% |
| 2017 | 2017-12-31 | $17.72 | $7.02 | +65.52% |
| 2016 | 2016-12-31 | $10.71 | -$4.16 | −27.96% |
| 2015 | 2015-12-31 | $14.86 | $2.74 | +22.56% |
| 2014 | 2014-12-31 | $12.13 | $7.89 | +185.94% |
| 2013 | 2013-12-31 | $4.24 | $1.69 | +66.07% |
| 2012 | 2012-12-31 | $2.55 | -$0.21 | −7.53% |
| 2011 | 2011-12-31 | $2.76 | -$0.97 | −26.09% |
| 2010 | 2010-12-31 | $3.74 | -$0.52 | −12.15% |
| 2009 | 2009-12-31 | $4.25 | — | — |
Alnylam Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.13 | $5.89 | +138.81% |
| Q1 2026 | 2026-03-31 | $8.06 | $4.79 | +146.43% |
| Q4 2025 | 2025-12-31 | $5.96 | $5.44 | +1048.94% |
| Q3 2025 | 2025-09-30 | $1.77 | $1.52 | +606.74% |
| Q2 2025 | 2025-06-30 | $4.24 | $4.26 | — |
| Q1 2025 | 2025-03-31 | $3.27 | $5.00 | — |
| Q4 2024 | 2024-12-31 | $0.52 | $2.27 | — |
| Q3 2024 | 2024-09-30 | $0.25 | $1.57 | — |
| Q2 2024 | 2024-06-30 | -$0.02 | $3.24 | — |
| Q1 2024 | 2024-03-31 | -$1.73 | $0.35 | — |
| Q4 2023 | 2023-12-31 | -$1.75 | -$0.48 | — |
| Q3 2023 | 2023-09-30 | -$1.32 | -$0.77 | — |
| Q2 2023 | 2023-06-30 | -$3.27 | -$4.72 | — |
| Q1 2023 | 2023-03-31 | -$2.09 | -$5.41 | — |
| Q4 2022 | 2022-12-31 | -$1.28 | -$6.17 | — |
| Q3 2022 | 2022-09-30 | -$0.55 | -$6.88 | — |
| Q2 2022 | 2022-06-30 | $1.45 | -$5.74 | −79.78% |
| Q1 2022 | 2022-03-31 | $3.32 | -$4.57 | −57.91% |
| Q4 2021 | 2021-12-31 | $4.89 | -$3.83 | −43.93% |
| Q3 2021 | 2021-09-30 | $6.33 | -$4.13 | −39.53% |
| Q2 2021 | 2021-06-30 | $7.20 | -$4.91 | −40.55% |
| Q1 2021 | 2021-03-31 | $7.89 | -$4.03 | −33.81% |
| Q4 2020 | 2020-12-31 | $8.73 | -$4.10 | −31.93% |
| Q3 2020 | 2020-09-30 | $10.46 | -$3.97 | −27.53% |
| Q2 2020 | 2020-06-30 | $12.10 | -$3.71 | −23.47% |
| Q1 2020 | 2020-03-31 | $11.93 | -$2.61 | −17.97% |
| Q4 2019 | 2019-12-31 | $12.82 | -$0.04 | −0.34% |
| Q3 2019 | 2019-09-30 | $14.44 | -$0.20 | −1.39% |
| Q2 2019 | 2019-06-30 | $15.81 | -$0.30 | −1.87% |
| Q1 2019 | 2019-03-31 | $14.54 | -$2.93 | −16.76% |
| Q4 2018 | 2018-12-31 | $12.87 | -$4.86 | −27.39% |
| Q3 2018 | 2018-09-30 | $14.64 | $3.18 | +27.71% |
| Q2 2018 | 2018-06-30 | $16.12 | $3.87 | +31.61% |
| Q1 2018 | 2018-03-31 | $17.47 | $7.81 | +80.92% |
| Q4 2017 | 2017-12-31 | $17.72 | $7.02 | +65.52% |
| Q3 2017 | 2017-09-30 | $11.46 | -$0.37 | −3.13% |
| Q2 2017 | 2017-06-30 | $12.25 | -$0.59 | −4.60% |
| Q1 2017 | 2017-03-31 | $9.65 | -$4.26 | −30.61% |
| Q4 2016 | 2016-12-31 | $10.71 | -$4.16 | −27.96% |
| Q3 2016 | 2016-09-30 | $11.83 | -$3.77 | −24.15% |
| Q2 2016 | 2016-06-30 | $12.84 | -$3.83 | −22.96% |
| Q1 2016 | 2016-03-31 | $13.91 | -$3.86 | −21.71% |
| Q4 2015 | 2015-12-31 | $14.86 | $2.74 | +22.56% |
| Q3 2015 | 2015-09-30 | $15.60 | $3.81 | +32.26% |
| Q2 2015 | 2015-06-30 | $16.66 | $4.32 | +34.97% |
| Q1 2015 | 2015-03-31 | $17.77 | $5.12 | +40.46% |
| Q4 2014 | 2014-12-31 | $12.13 | $7.89 | +185.94% |
| Q3 2014 | 2014-09-30 | $11.80 | $7.09 | +150.66% |
| Q2 2014 | 2014-06-30 | $12.35 | $7.41 | +150.21% |
| Q1 2014 | 2014-03-31 | $12.65 | $7.64 | +152.30% |
| Q4 2013 | 2013-12-31 | $4.24 | $1.69 | +66.07% |
| Q3 2013 | 2013-09-30 | $4.71 | $1.32 | +39.13% |
| Q2 2013 | 2013-06-30 | $4.93 | $1.31 | +36.26% |
| Q1 2013 | 2013-03-31 | $5.01 | $1.21 | +31.83% |
| Q4 2012 | 2012-12-31 | $2.55 | -$0.21 | −7.53% |
| Q3 2012 | 2012-09-30 | $3.38 | $0.39 | +12.91% |
| Q2 2012 | 2012-06-30 | $3.62 | $0.42 | +13.11% |
| Q1 2012 | 2012-03-31 | $3.80 | $0.37 | +10.68% |
| Q4 2011 | 2011-12-31 | $2.76 | -$0.97 | −26.09% |
| Q3 2011 | 2011-09-30 | $3.00 | -$0.81 | −21.38% |
| Q2 2011 | 2011-06-30 | $3.20 | -$0.73 | −18.56% |
| Q1 2011 | 2011-03-31 | $3.44 | — | — |
| Q4 2010 | 2010-12-31 | $3.74 | -$0.52 | −12.15% |
| Q3 2010 | 2010-09-30 | $3.81 | — | — |
| Q2 2010 | 2010-06-30 | $3.93 | — | — |
| Q4 2009 | 2009-12-31 | $4.25 | — | — |
Alnylam Pharmaceuticals book value per share trends
Over the last five fiscal years, Alnylam Pharmaceuticals's book value per share decreased from $8.73 to $5.96, a change of -$2.77. The latest reported quarter, Q2 2026, shows $10.13.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗